A Phase 2/3 Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents
Phase of Trial: Phase II/III
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational
- Sponsors Gilead Sciences
- 03 Nov 2017 Status changed from active, no longer recruiting to completed.
- 19 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
- 10 Jun 2017 Biomarkers information updated